Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of odiparcil for prevention of venous thromboembolism after total knee replacement
2004-000610-39Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of odiparcil in venous thromboembolism (VTE) (2 arms), sponsored by GSK. Primary endpoints: Incidence of total venous thromboembolism and Safety of odiparcil. Started Aug 2005; status: completed.
02
Drugs
odiparcil
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2004-000610-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000610-39.